India still attractive for Japanese pharma despite Daiichi Sankyo's Ranbaxy experience | 30 April, 2015

Japanese drug firms eyeing international investments should not be put off by Daiichi Sankyo’s turbulent ownership of Ranbaxy according to an Indian delegation in Tokyo last week to seek collaborations.

Representatives from the India Brand Equity Foundation (IBEF), Pharmexcil and the Indian Government told delegates at CPhI Japan in Tokyo that India's large, growing market is an attractive opportunity for Japanese firms.

• Sandhu described Daiichi's investment in Ranbaxy as a strategic move and not every strategic move gives you money. But I am happy that when they sold their 8.9% stake to Sun Pharma, they made money. So India as a nation holds great potential infrastructure is an area in which the Indian Government is requesting help from its Japanese counterparts Sandhu said, adding that in terms of R&D where we need help to take the business of pharma forward. He also referenced arguing that - Even a company like Daiichi Sankyo has not lost money. They sold their Ranbaxy stocks to Sun Pharma, so practically they have not lost money.